Covid 19 Research using Clinical Trials (Home Page)
Report for D018805: Sepsis NIH
(Synonyms: Sepsi, Sepsis)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (16)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3122 | White Sender in Acknowledgement Wiki | 0.45 |
| drug83 | AMA Acknowledgement Drug Pricing Wiki | 0.45 |
| drug2359 | Racial Inequality Highlighted Wiki | 0.45 |
| drug1654 | MMR vaccine Wiki | 0.45 |
| drug1886 | No Racial Inequality Highlighting Wiki | 0.45 |
| drug2168 | Placebo videos Wiki | 0.45 |
| drug2941 | Toraymyxin PMX-20R (PMX Cartridge) Wiki | 0.45 |
| drug140 | Acknowledgement Racial Injustice AMA Wiki | 0.45 |
| drug2182 | Plasma expansion with Ringer's Acetate Wiki | 0.45 |
| drug2387 | Recombinant human alkaline phosphatase Wiki | 0.45 |
| drug3123 | White Sender in Informational Videos Wiki | 0.45 |
| drug163 | African American Sender Acknowledgement Wiki | 0.45 |
| drug164 | African American Sender in Informational Videos. Wiki | 0.45 |
| drug38 | 300 mg of omega3-FA Wiki | 0.45 |
| drug3192 | bacTRL-Spike Wiki | 0.45 |
| drug2122 | Placebo Wiki | 0.05 |
Correlated MeSH Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012772 | Shock, Septic NIH | 0.45 |
| D019446 | Endotoxemia NIH | 0.45 |
| D014115 | Toxemia NIH | 0.45 |
| D018746 | Systemic Inflammatory Response Syndrome NIH | 0.26 |
| D058186 | Acute Kidney Injury NIH | 0.21 |
| D012769 | Shock, NIH | 0.18 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100806 | Sepsis HPO | 1.00 |
| HP:0001919 | Acute kidney injury HPO | 0.21 |
There are 5 clinical trials
Clinical Trials
1 MR-Evaluation of Renal Function In Septic Patients
A study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to COVID-19 or other agents.
NCT02765191 Sepsis, Severe Acute Kidney Injury COVID-19 Other: Plasma expansion with Ringer's Acetate MeSH:Sepsis Acute Kidney Injury
HPO:Acute kidney injury Sepsis
Primary Outcomes
Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST), compared to baseline measurement
Measure: Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus Time: When achieved according to protocol, approximately 3-10 minutes after intervention
Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) during baseline measurement.
Measure: Descriptive renal oxygenation and blood flow in critical illness due to sepsis Time: During Critical illness - at one time point
Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) images stratified in groups in regards to KDIGO grade during exam.
Measure: Descriptive renal oxygenation and blood flow in critical illness in no/low grade AKI or high grade AKI. Time: During Critical illness - at one time point
2 Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
Primary Outcomes
Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST), compared to baseline measurement
Measure: Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus Time: When achieved according to protocol, approximately 3-10 minutes after interventionDescription: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) during baseline measurement.
Measure: Descriptive renal oxygenation and blood flow in critical illness due to sepsis Time: During Critical illness - at one time pointDescription: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) images stratified in groups in regards to KDIGO grade during exam.
Measure: Descriptive renal oxygenation and blood flow in critical illness in no/low grade AKI or high grade AKI. Time: During Critical illness - at one time pointProspective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
NCT04352985 Septic Shock Endotoxemia COVID Corona Virus Infection Sepsis, Severe Device: Toraymyxin PMX-20R (PMX Cartridge) MeSH:Shock, Septic Endotoxemia Sepsis Coronavirus Infections Severe Acute Respiratory Syndrome Shock
HPO:Sepsis
3 SQuISH-COVID: A Pilot Study
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases.
NCT04372472 Sepsis COVID-19 MeSH:Sepsis
HPO:Sepsis
Primary Outcomes
Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.
Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection. Time: Day of enrollment through Day 5
4 A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI
Primary Outcomes
Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.
Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection. Time: Day of enrollment through Day 5Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. 1400 patients will be included in the study that is conducted in approx. 100 ICU's in Europe and North America There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.
NCT04411472 Acute Kidney Injury Due to Sepsis Biological: Recombinant human alkaline phosphatase Other: Placebo MeSH:Sepsis Acute Kidney Injury
HPO:Acute kidney injury Sepsis
Primary Outcomes
Description: To demonstrate an effect of recAP on 28 day all cause mortality
Measure: 28-day all-cause mortality Time: 28 days
Secondary Outcomes
Description: MAKE 90: dead or on RRT or ≥25% decline in estimated glomerular filtration rate (eGFR) on Day 90 relative to the known or assumed pre-AKI reference level.
Measure: To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE). Time: 90 Days
Description: Days alive and free of organ support through Day 28, i.e., days alive with no MV, RRT, vasopressors or inotropes (with death within 28 days counting as zero days).
Measure: To investigate the effect of recAP on use of organ support, i.e., mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors or inotropes. Time: 28 days
Description: Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).
Measure: To investigate the effect of recAP on length of stay (LOS) in ICU. Time: 28 days
Description: Time to death through Day 90.
Measure: To investigate the effect of recAP on 90-day allcause mortality Time: 90 days
5 Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation
Primary Outcomes
Description: To demonstrate an effect of recAP on 28 day all cause mortality
Measure: 28-day all-cause mortality Time: 28 daysSecondary Outcomes
Description: MAKE 90: dead or on RRT or ≥25% decline in estimated glomerular filtration rate (eGFR) on Day 90 relative to the known or assumed pre-AKI reference level.
Measure: To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE). Time: 90 DaysDescription: Days alive and free of organ support through Day 28, i.e., days alive with no MV, RRT, vasopressors or inotropes (with death within 28 days counting as zero days).
Measure: To investigate the effect of recAP on use of organ support, i.e., mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors or inotropes. Time: 28 daysDescription: Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).
Measure: To investigate the effect of recAP on length of stay (LOS) in ICU. Time: 28 daysDescription: Time to death through Day 90.
Measure: To investigate the effect of recAP on 90-day allcause mortality Time: 90 daysThe objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.
NCT04475081 Sepsis Syndrome Biological: MMR vaccine MeSH:Sepsis Toxemia Systemic Inflammatory Response Syndrome
HPO:Sepsis
Primary Outcomes
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of myeloid-derived suppressor cells (MDSCs) Time: 14 days post-vaccination
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 30 days post vaccination
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 60 days post vaccination
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 12 months post vaccination
Secondary Outcomes
Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 14 days post-vaccination
Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 30 days post-vaccination
Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 60 days post-vaccination
Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 12 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 14 days post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 30 days post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 60 days post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 3 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 4 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 5 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 6 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 7 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 8 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 9 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 10 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 11 months post-vaccination
Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 12 months post-vaccination
HPO Nodes
HP:0100806: Sepsis
Genes 78
PLEC CYBB CYBC1 VPS33A IL7R CYBA LIG4 LMOD1 IL2RG ALOX12B IL7R G6PC3 RET BLNK WIPF1 SULT2B1 IL2RG NIPAL4 CD79A ECE1 FOXP3 EDNRB NCF2 APC CTCF SEMA3C SERAC1 IKZF1 MNX1 CXCR4 IGHM MYH11 ABCA12 NFKB2 RAG1 TCF3 TFRC ELANE SAMD9 PIK3R1 MYLK RAG2 CYP4F22 NCF4 WAS COG4 GALT ADA AK2 RMRP ACTG2 CTNNB1 NRTN NCF1 FERMT3 HYOU1 AK2 BTK ATP7A CD40LG SEMA3D ALOXE3 TGM1 MMUT ITGB4 LRRC8A PGM3 DCLRE1C HLA-B EDN3 CTLA4 LIPN GDNF CD79B CHD7 IGLL1 RAG1 SDR9C7
Primary Outcomes
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of myeloid-derived suppressor cells (MDSCs) Time: 14 days post-vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 30 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 60 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 12 months post vaccinationSecondary Outcomes
Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 14 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 30 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 60 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 12 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 14 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 30 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 60 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 3 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 4 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 5 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 6 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 7 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 8 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 9 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 10 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 11 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 12 months post-vaccination